Literature DB >> 2470148

Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.

G Poli1, J M Orenstein, A Kinter, T M Folks, A S Fauci.   

Abstract

Promonocytic (U1) and T lymphocytic (ACH-2) cell lines chronically infected with human immunodeficiency virus type 1 (HIV-1) constitutively express low levels of virus, but expression can be induced by phorbol esters and cytokines. Whereas ACH-2 cells produce infectious virions, U1 cells produce defective, noninfectious particles. Although 3'-azido-3'-deoxythimidine (AZT) prevented acute HIV infection of susceptible cells, it did not prevent the induction of HIV expression in the infected cell lines. In contrast, interferon alpha (IFN-alpha) inhibited the release of reverse transcriptase and viral antigens into the culture supernatant after phorbol ester stimulation of both cell lines. Further, IFN-alpha suppressed the production or release (or both) of whole HIV virions, but had no effect on the amount of cell-associated viral proteins. Also, after phorbol ester stimulation of ACH-2 cells, IFN-alpha reduced the number of infectious viral particles secreted into the culture supernatant, but had no effect on the infectivity of cell-associated virus. These findings lend support to the combined use of antiviral agents that have action at both the early (AZT) and the late (IFN-alpha) stages of HIV replication.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470148     DOI: 10.1126/science.2470148

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  110 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40.

Authors:  J Verhoef; G Gekker; A Erice; P K Peterson; H H Balfour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

Review 3.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

4.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

5.  Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Authors:  Satish K Pillai; Mohamed Abdel-Mohsen; John Guatelli; Mark Skasko; Alexander Monto; Katsuya Fujimoto; Steven Yukl; Warner C Greene; Helen Kovari; Andri Rauch; Jacques Fellay; Manuel Battegay; Bernard Hirschel; Andrea Witteck; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard; Joseph K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

6.  Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.

Authors:  Atsushi Okumura; Gengshi Lu; Ian Pitha-Rowe; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-24       Impact factor: 11.205

7.  Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.

Authors:  Ryuta Sakuma; Amber A Mael; Yasuhiro Ikeda
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

8.  Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.

Authors:  M Yoshikawa; H Fukui; H Kojima; H Yoshiji; T Sakamoto; H Imazu; T Nakanani; Y Matsumura; S Kuriyama; J Yamao
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

9.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 10.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.